Sensible Antisense

Finding Could Yield New Liver Cancer Therapy

Thomas SchmittgenHepatocellular carcinoma, or liver cancer, kills an estimated 549,000 people annually worldwide. Recent findings by researchers at the OSUCCC – James and the Mayo Clinic show that it is possible to target and block a microRNA that is important in the disease, perhaps offering a new therapy for the malignancy.

The animal study focused on microRNA-221 (miR-221), a molecule that is consistently present at abnormally high levels in liver cancer.

To control the problem molecule, researchers designed a second molecule as a mirror image of the first. The mirror molecule, called an antisense oligonucleotide, selectively bound to and blocked the action of miR-221 in human liver cancer that was transplanted in mice. The treatment significantly prolonged the animals’ lives and promoted the activity of important tumor-suppressor genes.

“Liver cancer generally has a poor prognosis, so we badly need new treatment strategies,” says principal investigator Thomas Schmittgen, PhD, a member of the OSUCCC – James Experimental Therapeutics Program.

Schmittgen and colleagues injected liver cancer cells labeled with the luminescent lightning-bug protein known as luciferase into the livers of mice, then used bioluminescence imaging to monitor tumor growth. When the tumors reached an appropriate size, one group of animals received the anti-miR molecule while the other group received a control molecule.

After treatment with the antisense oligonucleotide, half of the treated animals were alive at 10 weeks versus none of the controls. Also, the antisense oligonucleotide significantly reduced levels of miR-221 in both tumor and normal liver samples. And treatment with the antisense oligonucleotide caused a three-fold increase in the activity of three tumor-suppressor genes that are blocked by miR-221 in liver cancer.

“Overall, this study provides proof-of-principle for further development of microRNA-targeted therapies for hepatocellular carcinomas,” Schmittgen says.

Published in the journal Cancer Research.

Sign up to receive publications from the OSUCCC – James

Sign Up Now

Contact The James

General Inquiries


800-293-5066


Email



Address


460 W. 10th Avenue
Columbus, OH 43210


Contact Us